NL8003740A - Nieuw therapeutisch preparaat en de toepassing en bereiding daarvan. - Google Patents

Nieuw therapeutisch preparaat en de toepassing en bereiding daarvan. Download PDF

Info

Publication number: NL8003740A
Authority: NL; Netherlands
Prior art keywords: group; carbon atoms; alkyl; preparation according; active substance
Prior art date: 1979-07-02

Application number

NL8003740A

Other languages

English (en)

Dutch (nl)

Original Assignee

Sandoz Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1979-07-02

Filing date

1980-06-27

Publication date

1981-01-06

1980-06-27 Application filed by Sandoz Ag filed Critical Sandoz Ag

1981-01-06 Publication of NL8003740A publication Critical patent/NL8003740A/nl

Links

238000002360 preparation method Methods 0.000 title claims description 23
230000001225 therapeutic effect Effects 0.000 title claims description 5
239000013543 active substance Substances 0.000 claims description 32
125000004432 carbon atom Chemical group C* 0.000 claims description 28
125000000217 alkyl group Chemical group 0.000 claims description 16
150000001875 compounds Chemical class 0.000 claims description 13
-1 alkanoyl radical Chemical class 0.000 claims description 12
125000003545 alkoxy group Chemical group 0.000 claims description 8
239000002876 beta blocker Substances 0.000 claims description 7
229910052739 hydrogen Inorganic materials 0.000 claims description 7
125000003277 amino group Chemical group 0.000 claims description 6
239000001257 hydrogen Substances 0.000 claims description 6
239000002249 anxiolytic agent Substances 0.000 claims description 5
125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 5
229910052736 halogen Inorganic materials 0.000 claims description 5
150000002367 halogens Chemical class 0.000 claims description 5
125000003118 aryl group Chemical group 0.000 claims description 4
125000003310 benzodiazepinyl group Chemical group N1N=C(C=CC2=C1C=CC=C2)* 0.000 claims description 4
239000000460 chlorine Substances 0.000 claims description 4
150000002431 hydrogen Chemical class 0.000 claims description 4
125000004442 acylamino group Chemical group 0.000 claims description 3
125000004423 acyloxy group Chemical group 0.000 claims description 3
125000003710 aryl alkyl group Chemical group 0.000 claims description 3
125000000753 cycloalkyl group Chemical group 0.000 claims description 3
125000001041 indolyl group Chemical group 0.000 claims description 3
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 3
LEVJVKGPFAQPOI-UHFFFAOYSA-N phenylmethanone Chemical compound O=[C]C1=CC=CC=C1 LEVJVKGPFAQPOI-UHFFFAOYSA-N 0.000 claims description 3
BSILYSDPCDWRTD-UHFFFAOYSA-N 1-(1h-indol-2-yloxy)-3-(propan-2-ylamino)propan-2-ol Chemical compound C1=CC=C2NC(OCC(O)CNC(C)C)=CC2=C1 BSILYSDPCDWRTD-UHFFFAOYSA-N 0.000 claims description 2
125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 claims description 2
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 2
125000004644 alkyl sulfinyl group Chemical group 0.000 claims description 2
125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 2
125000004414 alkyl thio group Chemical group 0.000 claims description 2
125000002947 alkylene group Chemical group 0.000 claims description 2
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 2
125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims description 2
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 2
125000004093 cyano group Chemical group *C#N 0.000 claims description 2
125000005843 halogen group Chemical group 0.000 claims description 2
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
238000004519 manufacturing process Methods 0.000 claims description 2
238000000034 method Methods 0.000 claims description 2
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 2
229910052760 oxygen Inorganic materials 0.000 claims description 2
239000001301 oxygen Substances 0.000 claims description 2
DEQPQVNEKHSACA-UHFFFAOYSA-N propan-2-yl 1h-indole-2-carboxylate Chemical compound C1=CC=C2NC(C(=O)OC(C)C)=CC2=C1 DEQPQVNEKHSACA-UHFFFAOYSA-N 0.000 claims description 2
229910052717 sulfur Inorganic materials 0.000 claims description 2
239000011593 sulfur Substances 0.000 claims description 2
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 2
ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 claims 2
229910052757 nitrogen Inorganic materials 0.000 claims 2
MHPGCNILHJVWJP-UHFFFAOYSA-N 1-indol-1-yloxy-3-(propan-2-ylamino)propan-2-ol Chemical compound C1=CC=C2N(OCC(O)CNC(C)C)C=CC2=C1 MHPGCNILHJVWJP-UHFFFAOYSA-N 0.000 claims 1
125000001589 carboacyl group Chemical group 0.000 claims 1
125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims 1
239000000825 pharmaceutical preparation Substances 0.000 claims 1
239000001294 propane Substances 0.000 claims 1
239000000203 mixture Substances 0.000 description 13
208000019901 Anxiety disease Diseases 0.000 description 9
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 6
230000036506 anxiety Effects 0.000 description 5
230000000949 anxiolytic effect Effects 0.000 description 5
229960003932 cloxazolam Drugs 0.000 description 5
ZIXNZOBDFKSQTC-UHFFFAOYSA-N cloxazolam Chemical compound C12=CC(Cl)=CC=C2NC(=O)CN2CCOC21C1=CC=CC=C1Cl ZIXNZOBDFKSQTC-UHFFFAOYSA-N 0.000 description 5
229960002508 pindolol Drugs 0.000 description 5
PHUTUTUABXHXLW-UHFFFAOYSA-N pindolol Chemical compound CC(C)NCC(O)COC1=CC=CC2=NC=C[C]12 PHUTUTUABXHXLW-UHFFFAOYSA-N 0.000 description 5
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
150000003839 salts Chemical class 0.000 description 4
229920002261 Corn starch Polymers 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
125000002252 acyl group Chemical group 0.000 description 3
239000002775 capsule Substances 0.000 description 3
238000000576 coating method Methods 0.000 description 3
239000008120 corn starch Substances 0.000 description 3
239000008298 dragée Substances 0.000 description 3
230000000694 effects Effects 0.000 description 3
238000002156 mixing Methods 0.000 description 3
239000000843 powder Substances 0.000 description 3
239000000243 solution Substances 0.000 description 3
239000000126 substance Substances 0.000 description 3
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
108010010803 Gelatin Proteins 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
239000000674 adrenergic antagonist Substances 0.000 description 2
229940097320 beta blocking agent Drugs 0.000 description 2
239000001768 carboxy methyl cellulose Substances 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
229910052801 chlorine Inorganic materials 0.000 description 2
239000011248 coating agent Substances 0.000 description 2
239000008119 colloidal silica Substances 0.000 description 2
125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 description 2
229920000159 gelatin Polymers 0.000 description 2
239000008273 gelatin Substances 0.000 description 2
239000007903 gelatin capsule Substances 0.000 description 2
235000019322 gelatine Nutrition 0.000 description 2
235000011852 gelatine desserts Nutrition 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
239000008101 lactose Substances 0.000 description 2
235000019359 magnesium stearate Nutrition 0.000 description 2
230000002093 peripheral effect Effects 0.000 description 2
125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 2
208000011580 syndromic disease Diseases 0.000 description 2
239000000454 talc Substances 0.000 description 2
229910052623 talc Inorganic materials 0.000 description 2
NXWGWUVGUSFQJC-GFCCVEGCSA-N (2r)-1-[(2-methyl-1h-indol-4-yl)oxy]-3-(propan-2-ylamino)propan-2-ol Chemical compound CC(C)NC[C@@H](O)COC1=CC=CC2=C1C=C(C)N2 NXWGWUVGUSFQJC-GFCCVEGCSA-N 0.000 description 1
YHPFENFSGCXRKE-UHFFFAOYSA-N 1H-pyrido[4,3-b]azepine Chemical compound N1C2=C(C=CC=C1)C=NC=C2 YHPFENFSGCXRKE-UHFFFAOYSA-N 0.000 description 1
RPBFCRRDMIDLOE-UHFFFAOYSA-N 2-methyl-n-[3-[(2-methyl-1h-indol-4-yl)oxy]-2-phenylmethoxypropyl]propan-2-amine Chemical compound C1=CC=C2NC(C)=CC2=C1OCC(CNC(C)(C)C)OCC1=CC=CC=C1 RPBFCRRDMIDLOE-UHFFFAOYSA-N 0.000 description 1
125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical class OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical group OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
208000020446 Cardiac disease Diseases 0.000 description 1
208000024172 Cardiovascular disease Diseases 0.000 description 1
229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
239000005977 Ethylene Substances 0.000 description 1
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 1
229920001800 Shellac Polymers 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical group C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
239000002253 acid Substances 0.000 description 1
238000013019 agitation Methods 0.000 description 1
239000000783 alginic acid Substances 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
229960001126 alginic acid Drugs 0.000 description 1
150000004781 alginic acids Chemical class 0.000 description 1
125000001931 aliphatic group Chemical group 0.000 description 1
XXROGKLTLUQVRX-UHFFFAOYSA-N allyl alcohol Chemical group OCC=C XXROGKLTLUQVRX-UHFFFAOYSA-N 0.000 description 1
230000000049 anti-anxiety effect Effects 0.000 description 1
150000001558 benzoic acid derivatives Chemical class 0.000 description 1
125000001231 benzoyloxy group Chemical group C(C1=CC=CC=C1)(=O)O* 0.000 description 1
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
230000036772 blood pressure Effects 0.000 description 1
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
229910052794 bromium Inorganic materials 0.000 description 1
KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
229910000019 calcium carbonate Inorganic materials 0.000 description 1
235000010216 calcium carbonate Nutrition 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
229940105329 carboxymethylcellulose Drugs 0.000 description 1
229940096529 carboxypolymethylene Drugs 0.000 description 1
239000000969 carrier Substances 0.000 description 1
229940081734 cellulose acetate phthalate Drugs 0.000 description 1
238000011260 co-administration Methods 0.000 description 1
239000007859 condensation product Substances 0.000 description 1
229940109275 cyclamate Drugs 0.000 description 1
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
238000009826 distribution Methods 0.000 description 1
230000002526 effect on cardiovascular system Effects 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
230000000763 evoking effect Effects 0.000 description 1
239000002360 explosive Substances 0.000 description 1
150000002191 fatty alcohols Chemical class 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000019634 flavors Nutrition 0.000 description 1
239000011737 fluorine Substances 0.000 description 1
229910052731 fluorine Inorganic materials 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
239000008187 granular material Substances 0.000 description 1
238000005469 granulation Methods 0.000 description 1
230000003179 granulation Effects 0.000 description 1
208000019622 heart disease Diseases 0.000 description 1
239000008240 homogeneous mixture Substances 0.000 description 1
239000003701 inert diluent Substances 0.000 description 1
229910052740 iodine Inorganic materials 0.000 description 1
239000011630 iodine Substances 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
239000007788 liquid Substances 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
229960003134 mepindolol Drugs 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
CWYZDPHNAGSFQB-UHFFFAOYSA-N n-propylbutan-1-amine Chemical compound CCCCNCCC CWYZDPHNAGSFQB-UHFFFAOYSA-N 0.000 description 1
125000001038 naphthoyl group Chemical group C1(=CC=CC2=CC=CC=C12)C(=O)* 0.000 description 1
125000001624 naphthyl group Chemical group 0.000 description 1
230000002981 neuropathic effect Effects 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
VCCZBYPHZRWKFY-XIKOKIGWSA-N oxazolam Chemical compound C1([C@]23C4=CC(Cl)=CC=C4NC(=O)CN2C[C@H](O3)C)=CC=CC=C1 VCCZBYPHZRWKFY-XIKOKIGWSA-N 0.000 description 1
229950006124 oxazolam Drugs 0.000 description 1
239000008194 pharmaceutical composition Substances 0.000 description 1
239000000049 pigment Substances 0.000 description 1
229920002689 polyvinyl acetate Polymers 0.000 description 1
239000011118 polyvinyl acetate Substances 0.000 description 1
229940075065 polyvinyl acetate Drugs 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000000750 progressive effect Effects 0.000 description 1
125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
239000004208 shellac Substances 0.000 description 1
ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
229940113147 shellac Drugs 0.000 description 1
235000013874 shellac Nutrition 0.000 description 1
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
125000000547 substituted alkyl group Chemical group 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
230000002195 synergetic effect Effects 0.000 description 1
230000035488 systolic blood pressure Effects 0.000 description 1
239000003826 tablet Substances 0.000 description 1
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 1
239000002562 thickening agent Substances 0.000 description 1
239000004408 titanium dioxide Substances 0.000 description 1
125000005425 toluyl group Chemical group 0.000 description 1
239000003204 tranquilizing agent Substances 0.000 description 1
230000002936 tranquilizing effect Effects 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
125000003258 trimethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])[*:1] 0.000 description 1
MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 1
FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 description 1
235000012141 vanillin Nutrition 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies

Landscapes

Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Neurosurgery (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Indole Compounds (AREA)

NL8003740A 1979-07-02 1980-06-27 Nieuw therapeutisch preparaat en de toepassing en bereiding daarvan. NL8003740A (nl)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DE2926653		1979-07-02
DE19792926653 DE2926653A1 (de)	1979-07-02	1979-07-02	Neue therapeutische verwendung von organischen verbindungen

Publications (1)

Publication Number	Publication Date
NL8003740A true NL8003740A (nl)	1981-01-06

Family

ID=6074700

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NL8003740A NL8003740A (nl)	1979-07-02	1980-06-27	Nieuw therapeutisch preparaat en de toepassing en bereiding daarvan.

Country Status (12)

Country	Link
JP (1)	JPS5610167A (ja)
AU (1)	AU5977880A (ja)
BE (1)	BE884082A (ja)
DE (1)	DE2926653A1 (ja)
FR (1)	FR2460671A1 (ja)
GB (1)	GB2052982A (ja)
IL (1)	IL60455A0 (ja)
IT (1)	IT8049133A0 (ja)
NL (1)	NL8003740A (ja)
PT (1)	PT71473B (ja)
SE (1)	SE8004872L (ja)
ZA (1)	ZA803988B (ja)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4468391A (en) *	1982-06-25	1984-08-28	Ayerst, Mckenna & Harrison, Inc.	Combination of β-adrenoceptor antagonists and anxiolytic agents
JP3282640B2 (ja) *	1993-01-27	2002-05-20	日本電信電話株式会社	海底光ケーブル

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE1919342A1 (de) *	1969-04-16	1970-12-03	Boehringer Sohn Ingelheim	Herzwirksame Kombinationspraeparate
FR2401661A1 (fr) *	1977-08-29	1979-03-30	Italiana Med Sint	Compositions pharmaceutiques a base de medicaments anxiolytiques et d'inhibiteurs du systeme b-adrenergique

1979
- 1979-07-02 DE DE19792926653 patent/DE2926653A1/de not_active Withdrawn
1980
- 1980-06-27 GB GB8021231A patent/GB2052982A/en not_active Withdrawn
- 1980-06-27 NL NL8003740A patent/NL8003740A/nl not_active Application Discontinuation
- 1980-06-30 FR FR8014517A patent/FR2460671A1/fr not_active Withdrawn
- 1980-06-30 BE BE1/9870A patent/BE884082A/fr unknown
- 1980-06-30 AU AU59778/80A patent/AU5977880A/en not_active Abandoned
- 1980-07-01 JP JP9047280A patent/JPS5610167A/ja active Pending
- 1980-07-01 PT PT71473A patent/PT71473B/pt unknown
- 1980-07-01 IT IT8049133A patent/IT8049133A0/it unknown
- 1980-07-01 SE SE8004872A patent/SE8004872L/ not_active Application Discontinuation
- 1980-07-01 IL IL60455A patent/IL60455A0/xx unknown
- 1980-07-02 ZA ZA00803988A patent/ZA803988B/xx unknown

Also Published As

Publication number	Publication date
BE884082A (fr)	1980-12-30
SE8004872L (sv)	1981-01-03
PT71473A (en)	1980-08-01
IT8049133A0 (it)	1980-07-01
ZA803988B (en)	1982-02-24
FR2460671A1 (fr)	1981-01-30
PT71473B (en)	1981-09-01
IL60455A0 (en)	1980-09-16
DE2926653A1 (de)	1981-01-22
GB2052982A (en)	1981-02-04
JPS5610167A (en)	1981-02-02
AU5977880A (en)	1981-01-15

Legal Events

Date	Code	Title	Description
1983-02-01	BV	The patent application has lapsed

Publication	Publication Date	Title
EP0017195B1 (en)	1984-07-04	Derivatives of 2,5-disubstituted-cyclohexane-1,3-diones, process for preparation thereof and pharmaceutical composition containing them
WO2001058450A2 (fr)	2001-08-16	Utilisation d'un antagoniste des recepteurs aux cannabinoides centraux pour la preparation de medicaments utiles pour faciliter l'arret de la consommation de tabac
JP2001521485A (ja)	2001-11-06	鎌状赤血球症のためのトリアリールメタン化合物
Wyrick et al.	1984	Hypolipidemic activity of phthalimide derivatives. 7. Structure-activity studies of indazolone analogs
JPS58185517A (ja)	1983-10-29	塩利尿作用を有する薬物
LV11899B (lv)	1998-03-20	Jauni adenozīna atvasinājumi, to iegūšanas paņēmiens
DE69520750T2 (de)	2001-09-13	IMMUNOTHERAPEUTISCHE IMIDE/AMIDE UND IHRE VERWENDUNG ZUR VERMINDERUNG DES TNFalpha-SPIEGELS
NL8003740A (nl)	1981-01-06	Nieuw therapeutisch preparaat en de toepassing en bereiding daarvan.
EP0412901B1 (fr)	1993-05-05	Utilisation de trifluorométhyl-phényltétrahydropyridines pour la préparation de médicaments destinés à combattre les troubles de la motricité intestinale
US4621101A (en)	1986-11-04	Pharmaceutical compositions with antianginal activity
US4157394A (en)	1979-06-05	Cardio-protective pharmaceutical composition
KR900006116B1 (ko)	1990-08-22	신규 디히드로피리딘의 제조 방법
JPS60158190A (ja)	1985-08-19	ヒダントイン誘導体およびその製法ならびにそれを含有する医薬
US7342038B2 (en)	2008-03-11	Substituted diphenyl indanone, indane and indole compounds and analogues thereof useful for the treatment or prevention of diseases characterized by abnormal cell proliferation
US6534497B1 (en)	2003-03-18	Substitute 11-phenyl-dibenzazepine compounds useful for the treatment or prevention of diseases characterized by abnormal cell proliferation
JP4009062B2 (ja)	2007-11-14	異常な細胞増殖を特徴とする疾患を治療または予防するために有用な、置換ジフェニルインダノン、インダン、およびインドール化合物およびそれらの類縁体
US20020128256A1 (en)	2002-09-12	Methods for the treatment or prevention of inflammatory diseases characterized by abnormal cell proliferation
TWI325317B (en)	2010-06-01	Appetite-stimulating agents and remedies for anorexia
US3981882A (en)	1976-09-21	Process for preparing 4-aryl of hetero-6-amino-3,4-dihydropyrid-2-one-3,5-dicarboxylic acid ester
US3966767A (en)	1976-06-29	2-Amino-4 H-pyrane
EP1032385A1 (en)	2000-09-06	Use of substituted diphenyl indanone, indane and indole compounds for the treatment or prevention of sickle cell disease, inflammatory diseases characterized by abnormal cellproliferation, diarrhe and scours
US3981893A (en)	1976-09-21	2-Amino-4 H-pyrane
US4696940A (en)	1987-09-29	Method for treating hypertension using 3-(4-imidazolylmethylene)-carbazic and dithiocarbazic acid esters
EP1032394A1 (en)	2000-09-06	Use of substituted 11-phenyl-dibenzazepine compounds for the treatment or prevention of sickle cell disease, inflammatory diseases characterized by abnormal cell proliferation, diarrhea and scour
US3951991A (en)	1976-04-20	4-Aryl-6-amino-3,4-dihydropyrid-2-one-3,5-dicarboxylic acid ester